Search Back New search Go to resultsDiseaseMain groupSupportive Therapy, ToxicityProtocol groupComplicationsDiseaseTumor Lysis SyndromeSubgroupICD10E88.3MeSHLymphoma, Mantle-CellLymphoma, T-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaTumor Lysis SyndromeSequenceChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceAllopurinolBalanced Crystalloid SolutionRasburicaseSupportive substanceAllopurinolBalanced Crystalloid SolutionRasburicaseSupportive substanceAllopurinolBalanced Crystalloid SolutionRasburicaseSupportive substanceAllopurinolBalanced Crystalloid SolutionRasburicaseNo. Substances2Protocol classificationTherapy classificationcurrent standardIntensityTherapy indicationTherapy phaseTherapy intentionsupportiveRisks only studiesPublicationAuthorJones GLDiseaseNeoplasien mit hohem Tumorlysesyndrom-RisikoNeoplasien mit mittlerem Tumorlysesyndrom-RisikoOriginManchester and Derriford Hospital,Plymouth, UKProtocols in Revision 2 protocols foundProtocols under revision.Tumor Lysis Syndrome Prophylaxis for High Risk Tumor Lysis Syndrome (PID312 V2.0)Prophylaxis of tumor lysis syndrome in intermediate risk tumor lysis syndrome (PID311 V1.0)
